Loading
companiesCompany
Ferring Pharmaceuticals
Ferring is the private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.
Overview
Ferring Pharmaceuticals, a private Swiss company based in Saint-Prex, brought the first bladder cancer gene therapy, Adstiladrin, or nadofaragene firadenovec, to market. Nadofaragene was approved in 2022 and launched in 2023 to 2024 after manufacturing scale-up, and the company also makes degarelix for prostate cancer alongside its reproductive medicine and gastroenterology franchises. OnCo links it to bladder and urothelial cancer and to the nadofaragene and degarelix drug records. Whether a gene therapy given into the bladder can hold its position as oncolytic virus and IL-15 competitors arrive is the open question. Nadofaragene firadenovec has its own page.
Headquarters
Saint-Prex, CH
Scorecard
All companies#116of 1244 companies, score 46
- approved products +12
- targets +2
- modalities +4
- regions +6
- registry trials +22
2 approved, 0 in phase 3, 0 earlier, 1 targets, 120 registry studies. Formula on the scorecards page.
Type
Website
ApprovedNon-replicating adenoviral gene therapy (intravesical)
Nadofaragene firadenovec · Adstiladrin
Nadofaragene firadenovec is the first gene therapy for bladder cancer: a virus that makes bladder cells produce interferon for weeks, given once every three months.
ApprovedGnRH antagonist depot
Degarelix · Firmagon
An injectable hormone blocker for prostate cancer that lowers testosterone within days without the initial surge caused by agonists.
Similar pages
- TechnologyIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
Shares Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer, A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer, Nadofaragene firadenovec, Bladder & urothelial cancer.
- TreatmentValrubicin
Shares Nadofaragene firadenovec, Bladder & urothelial cancer.
- TermBCG-unresponsive
Shares Nadofaragene firadenovec, Bladder & urothelial cancer.
- IdeaOncolytic viruses that make interleukin-12 only inside the tumour
Shares Nadofaragene firadenovec, Bladder & urothelial cancer.
- CancerNon-muscle-invasive bladder cancer
Shares Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC), Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer, A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer, Nadofaragene firadenovec.
- TreatmentBicalutamide
Shares Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients, Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer.
- TreatmentGoserelin / leuprolide (ovarian function suppression)
Shares Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients, Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer.
cancers
fronts
drugs
ApprovedGnRH antagonist depot
Degarelix · Firmagon
ApprovedNon-replicating adenoviral gene therapy (intravesical)
Nadofaragene firadenovec · Adstiladrin
trials
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular DiseaseA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerInvestigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsNeoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate CancerSafety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer